{{ languageVal }}
- English
-
Legal Services
Fiduciary Services
- AIFM & UCITS Management Company Services
- Accounting, Tax & Agency Services
- Commodity Pool Operator Services
- Company Secretarial & Board Support Services
- Conflict Review & Advisory Services
- Directorship Services
- Facilities Agent Services
- Permanent Office Solutions
- Power of Attorney & Proxy Agent Services
- Private Client Services
- Trustee Services
Fund Services
Regulatory & Compliance
-
Americas and Caribbean
Europe
-
PUT YOUR CAREER INTO GEAR
-
-
AI Act Set to Come into Force on 1 August 2024
02 Jul 2024The CLOser - June 2024
27 Jun 2024
Deals
Maples Advises Biohaven in Largest Take-Private Transaction in BVI
19 May 2022
Maples and Calder, the Maples Group's law firm, is pleased to have recently provided British Virgin Islands ("BVI") counsel to Biohaven Pharmaceutical Holding Company Ltd ("Biohaven"), in respect of definitive agreement regarding its acquisition by US pharmaceutical group, Pfizer. Notably, the transaction, valued at approximately US$11.6 billion, would be the largest take-private of a BVI listed entity to date when completed.
The acquisition is subject to, among other things, approval of the Biohaven shareholders. Once approved, the take-private will be executed as a BVI merger with Pfizer acquiring all outstanding shares of Biohaven and the calcitonin gene-related peptide ("CGRP") programmes. A new publicly traded company, New Biohaven, a research and development company will retain Biohaven's non-CGRP development stage pipeline programme.
Chris Newton, a Corporate Partner in the firm's BVI office, led the BVI legal team which included BVI Managing Partner Richard May (Corporate) and Partner Matthew Freeman (Dispute Resolution & Insolvency), Associate Amel Wehden (Corporate) and Chartered Legal Executive Chloe Harris (Corporate). The team acted alongside Biohaven's US counsel Sullivan & Cromwell.
Commenting on the transaction, Chris said, "This acquisition highlights the BVI's ability to attract and support innovative, cross-border M&A transactions and we are extremely pleased that the Maples Group continues to be at the forefront of this. We have supported the Biohaven team from incorporation and look forward to continuing to work with them in bringing a close to this next chapter."
This agreement follows the two companies 9 November 2021 collaboration for the commercialisation of rimegepant and zavegepant outside the US, where the firm also advised Biohaven.
The acquisition is subject to, among other things, approval of the Biohaven shareholders. Once approved, the take-private will be executed as a BVI merger with Pfizer acquiring all outstanding shares of Biohaven and the calcitonin gene-related peptide ("CGRP") programmes. A new publicly traded company, New Biohaven, a research and development company will retain Biohaven's non-CGRP development stage pipeline programme.
Chris Newton, a Corporate Partner in the firm's BVI office, led the BVI legal team which included BVI Managing Partner Richard May (Corporate) and Partner Matthew Freeman (Dispute Resolution & Insolvency), Associate Amel Wehden (Corporate) and Chartered Legal Executive Chloe Harris (Corporate). The team acted alongside Biohaven's US counsel Sullivan & Cromwell.
Commenting on the transaction, Chris said, "This acquisition highlights the BVI's ability to attract and support innovative, cross-border M&A transactions and we are extremely pleased that the Maples Group continues to be at the forefront of this. We have supported the Biohaven team from incorporation and look forward to continuing to work with them in bringing a close to this next chapter."
This agreement follows the two companies 9 November 2021 collaboration for the commercialisation of rimegepant and zavegepant outside the US, where the firm also advised Biohaven.
Related Services
Corporate
Advising on the laws of the BVI, the Cayman Islands, Ireland, Jersey and Luxembourg, our global corporate team provides expert legal advice to corporate clients on all corporate commercial matters. Our clients include major banks, multinationals and institutional investment firms, leading law and accountancy firms and a number of state / government entities across all industry sectors.
Related Contacts
Related Articles
-
Deals
Maples Group Advises Screaming Eagle on US$4.6 Billion Combination with Lionsgate's Studio Business
14 Jun 2024
-
Announcements
Maples Group's Latin American Practice Recognised at Latin Lawyer Awards for Advising on $1.5 Billion Arco Deal
06 Jun 2024
-
Deals
Maples Group Advises ifeel on its US$20 Million Series B Investment Round
05 Jun 2024
-
-
-
Deals
Maples Group Advises IHG Hotels Resorts on Landmark Licencing of Hotel Indigo Grand Cayman
04 Jun 2024
-
Deals
Maples Group Acts as Cayman Islands Counsel on the Transfer of Ownership of Inter Milan Football Club to Oaktree
03 Jun 2024
-
Announcements
Maples Group Appoints Suzanne Correy and Finn O'Hegarty as Co-Heads of Latin American Practice
31 May 2024